Synta Pharmaceuticals Corp., of Lexington, Mass., said a preclinical study found that ganetespib equally inhibits growth of Xalkori (crizotinib, Pfizer Inc.)-sensitive and crizotinib-resistant cancer cells driven by the EML4-ALK fusion protein, regardless of ALK mutation status

Formerly being developed by New York-based Pfizer Inc...Puma was founded last fall, reverse merged with a public shell and licensed clinical-stage kinase inhibitor neratinib from New York-based Pfizer Inc

Pfizer Inc., of New York, is facing a lawsuit alleging negligence and other allegations claiming that the firm failed to warn the medical community that antidepressant Zoloft (sertraline) carried a risk of congenital birth defects when taken during pregnancy

PolyMedix Inc., of Radnor, Pa., said lead defensing-mimetic antibiotic PMX-30063 demonstrated activity against 1,000 worldwide strains of Gram-positive staphylococci and streptococci clinical isolates, including strains resistant to Zyvox (linezolid, Pfizer Inc.), Cubicin (daptomycin, Cubist Pharmaceuticals Inc.) and methicillin

Biocon Ltd., of Bangalore, India, and Pfizer Inc., of New York, ended their alliance to commercialize Biocon's biosimilar versions of insulin and insulin analogue products, citing differing priorities for their respective biosimilars businesses

Pfizer Inc., of New York, faces a federal lawsuit filed by St. Louis-based law firm Carey, Danis & Lowe, alleging that birth defects resulted in a child after the mother was prescribed and ingested antidepressant drug Zoloft (sertraline) while pregnant

Results for the moderate dose level of addiction candidate EMB-001 were similar to those observed for positive control Chantix (varenicline, Pfizer Inc.), an FDA-approved smoking cessation product

Biocon Ltd., of Bangalore, India, and Pfizer Inc., of New York, ended their alliance to commercialize Biocon's biosimilar versions of insulin and insulin analogue products, citing differing priorities for their respective biosimilars businesses

and Pfizer Inc., both of New York, said the FDA extended the PDUFA date for their new drug application (NDA) for Eliquis (apixaban) by three months to June 28

Pfizer Inc., of New York, issued a statement regarding the use of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) in adults, 50 and older

Pfizer Inc., of New York, said the FDA accepted for review the new drug application for tafamidis meglumine, its oral treatment for transthyretin familial amyloid polyneuropathy, a rare, progressive and fatal neurodegenerative disease that affects about 8,000 patients worldwide

plc and Madison-N.J.-based Wyeth (now part of Pfizer Inc.), which are co-developing bapineuzumab, a Phase III-stage Alzheimer's disease candidate

Siemens also signed a deal with ViiV Healthcare Co., a joint venture between London-based GlaxoSmithKline plc and New York-based Pfizer Inc., for diagnostic tests related to Celsentri/Selzentry (maraviroc), a CCR5 co-receptor antagonist for CCR5-tropic HIV

Pfizer Inc., of New York, said the FDA approved kinase inhibitor Inlyta (axitinib) for treating patients with advanced renal cell carcinoma after failure of one prior systemic therapy

Trius Therapeutics Inc., of San Diego, said it earned a $5 million milestone payment from Bayer Pharma AG, of Leverkusen, Germany, for meeting efficacy and safety objectives in the pivotal Phase III study of the oral formulation of TR701-112 (tedizolid phosphate) compared to linezolid (Zyvox, Pfizer Inc.) in bacterial skin and skin structure infections (ABSSSI

II, of San Francisco, entered a collaborative development agreement with Pfizer Inc., of New York, to conduct a Phase III trial in Asia of Pfizer's investigational axitinib for the adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy

Developed by Veloxis through Phase II in the U.S., AtorFen demonstrated improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with Lipitor (atorvastatin, Pfizer Inc.) alone, as well as a significantly greater effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with Tricor (fenofibrate, Abbott) alone

Developed by Veloxis through Phase II in the U.S., AtorFen demonstrated improvements in HDL-C, triglycerides, VLDL and fibrinogen compared with Lipitor (atorvastatin, Pfizer Inc.) alone, as well as a significantly greater effect on non-HDL-C, LDL-C, triglycerides and total cholesterol compared with Tricor (fenofibrate, Abbott) alone

Antares Pharma Inc., of Ewing, N.J., has licensed to Pfizer Inc.'s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America...Pfizer Inc., of New York, said the FDA accepted for review its new drug application seeking approval of oral JAK inhibitor tofacitinib for moderate to severe active rheumatoid arthritis